Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has issued an announcement.
PharmAla Biotech has signed a supply agreement with Norway’s Østfold Hospital Trust to provide its LaNeo-branded MDMA for clinical research into MDMA as a potential treatment for major depressive disorder, following a competitive vendor review and extensive due diligence. The deal, which includes both financial and data-sharing components, underscores PharmAla’s strengthening role in Europe’s psychedelic medicine research ecosystem and leverages its established regional value chain, while also enhancing its clinical footprint by encouraging researchers to transition existing trial protocols to its LaNeo MDMA platform through dedicated support tools and potential data-sharing discounts.
The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.11 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.
Spark’s Take on TSE:MDMA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.
The score is primarily held back by weak financial fundamentals—deep losses and ongoing cash burn despite revenue growth—partly offset by a debt-free balance sheet. Technical indicators are mostly neutral, valuation is constrained by negative earnings and no dividend support, and recent corporate updates provide some positive execution and demand signals.
To see Spark’s full report on TSE:MDMA stock, click here.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology company specializing in the research, development and manufacturing of MDXX-class molecules, including MDMA, with a focus on alleviating the global shortage of clinical-grade MDMA for trials and select commercial uses while also developing novel MDMA derivatives. The company positions itself as a regulatory-focused provider and is currently the only firm supplying clinical-grade MDMA for patient treatments outside of clinical trials, supported by a growing portfolio of proprietary drug candidates such as its lead asset ALA-002.
Average Trading Volume: 189,375
Technical Sentiment Signal: Sell
Current Market Cap: C$10.89M
For a thorough assessment of MDMA stock, go to TipRanks’ Stock Analysis page.